ArticleTherapeutic advances in medical oncology2021

NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer.

Yuan Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.